[vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on April 18, 2022
Kenneth B. Chapman, MD – Director, Pain Medicine
Dr. Kenneth Chapman presents an overview of current dorsal root ganglion stimulation (DRG-S) applications, outcomes, and future directions. Dr. Chapman explains the main differences between DRG-S and spinal cord stimulation (SCS). He mentions that among several distinctions, DRG-S is applied at subthreshold amplitudes that are imperceptible, while SCS is paresthesia-dependent. Dr. Chapman also mentions that DRG-S can facilitate pain neuromodulation by influencing the endogenous opioid system. He emphasizes additional benefits of DRG-S, including the management of joint nociceptive pain as demonstrated by a heightened quality of life, physical function, and mental health. Additionally, Dr. Chapman describes prospective DRG-S studies for low back pain.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]
[/vc_column_text][/vc_column][/vc_row]